Clinical Trials in Birmingham, United Kingdom
338 recruiting
Showing 1–20 of 371 trials
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 2
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled127 locationsNCT06890884
Recruiting
Phase 3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Myelodysplastic SyndromeAnemia
Takeda300 enrolled154 locationsNCT07422480
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled261 locationsNCT06841354
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,700 enrolled99 locationsNCT05489705
Recruiting
Phase 3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals320 enrolled114 locationsNCT06719141
Recruiting
Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Kidney Disease
Takeda347 enrolled169 locationsNCT06963827
Recruiting
Phase 2
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Vertex Pharmaceuticals Incorporated24 enrolled43 locationsNCT07161037
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled200 locationsNCT06997497
Recruiting
Phase 3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Biliary Tract Cancer
AstraZeneca620 enrolled270 locationsNCT06467357
Recruiting
Phase 2
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Cushing's Disease
H. Lundbeck A/S18 enrolled27 locationsNCT06471829
Recruiting
Phase 1
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Huntington’s Disease
Alnylam Pharmaceuticals66 enrolled19 locationsNCT06585449
Recruiting
Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled233 locationsNCT07052903
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Pfizer3,501 enrolled170 locationsNCT07311850
Recruiting
Phase 2
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
Pompe Disease
Shionogi45 enrolled28 locationsNCT07123155
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
Asthma Acute
Connect Biopharm LLC160 enrolled59 locationsNCT06940141
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
COPD Acute Exacerbation
Connect Biopharm LLC160 enrolled53 locationsNCT06940154
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109